Literature DB >> 17466730

Exercise testing and training in a cancer rehabilitation program: the advantage of the steep ramp test.

Ingrid C De Backer1, Goof Schep, Adwin Hoogeveen, Gerard Vreugdenhil, Arnold D Kester, Eric van Breda.   

Abstract

OBJECTIVE: To compare the short maximal exercise capacity test (steep ramp test) with the submaximal test to determine the most appropriate exercise test in cancer rehabilitation.
DESIGN: A prospective study in which a submaximal test, a maximal short exercise capacity test (steep ramp test), and a maximal oxygen consumption test (Vo(2)max test) were performed before and after an 18-week training program. Vo(2)max testing, the criterion standard for the measurement of physical capacity, was compared with the submaximal test and the steep ramp test.
SETTING: Community hospital and physiotherapy. PARTICIPANTS: Thirty-seven cancer survivors (10 men, 27 women) treated with chemotherapy. The subjects' mean age +/- standard deviation (SD) was 48+/-11 years. INTERVENTION: An 18-week training program including strength training, interval aerobic training, and home-based activities (endurance). MAIN OUTCOME MEASURES: Estimated Vo(2)max (submaximal test) and maximal workload (steep ramp test) were assessed during the exercise tests and compared with the results of the Vo(2)max test.
RESULTS: A paired t test showed a significant improvement in Vo(2)max (+13%, P<.001) and maximal workload (+19%, P<.001) after the training program. This improvement was confirmed in the steep ramp test (maximal workload, +13%, P<.001) but not in the submaximal test (estimated Vo(2)max, +4%, P=.192). Pearson correlation quantified only a moderate correlation between the Vo(2)max test and the submaximal test and a high correlation between the Vo(2)max test and the steep ramp test. Intraclass correlation determined the test-retest reliability of the submaximal test (.873) and the steep ramp test (.996). A linear regression model (Vo(2)max, 6.7; steep ramp Wmax, +356.7) was estimated to predict Vo(2)max from the steep ramp test outcome, implying a prediction margin of +/-2 SDs (616 mL/min).
CONCLUSIONS: The submaximal test proved to be invalid, whereas the steep ramp test seems to be a practicable, reliable, and valid test for the assessment of the training dose. The steep ramp test can be regularly repeated during the training program, providing information needed to readjust the training dose according to the progress made.

Entities:  

Mesh:

Year:  2007        PMID: 17466730     DOI: 10.1016/j.apmr.2007.02.013

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  37 in total

1.  Short and long-term impairments of cardiopulmonary fitness level in previous childhood cancer cases: a systematic review.

Authors:  Vesile Yildiz Kabak; Patrick Calders; Tulin Duger; Jibril Mohammed; Eric van Breda
Journal:  Support Care Cancer       Date:  2018-09-25       Impact factor: 3.603

2.  Recruitment to and pilot results of the PACES randomized trial of physical exercise during adjuvant chemotherapy for colon cancer.

Authors:  Hanna van Waart; Martijn M Stuiver; Wim H van Harten; Edwin Geleijn; Marianne de Maaker-Berkhof; Jolanda Schrama; Maud M Geenen; Jetske M Meerum Terwogt; Simone M van den Heiligenberg; Jeannette A J H Hellendoorn-van Vreeswijk; Gabe S Sonke; Neil K Aaronson
Journal:  Int J Colorectal Dis       Date:  2017-11-09       Impact factor: 2.571

3.  Comparison of physiological response to cardiopulmonary exercise testing among cancer survivors and healthy controls.

Authors:  Riggs J Klika; Katharina S Golik; Scott N Drum; Kathleen E Callahan; William G Thorland
Journal:  Eur J Appl Physiol       Date:  2010-12-03       Impact factor: 3.078

4.  Design of the Physical exercise during Adjuvant Chemotherapy Effectiveness Study (PACES): a randomized controlled trial to evaluate effectiveness and cost-effectiveness of physical exercise in improving physical fitness and reducing fatigue.

Authors:  Hanna van Waart; Martijn M Stuiver; Wim H van Harten; Gabe S Sonke; Neil K Aaronson
Journal:  BMC Cancer       Date:  2010-12-07       Impact factor: 4.430

5.  Cardiopulmonary exercise testing in cancer rehabilitation: a systematic review.

Authors:  Charlotte N Steins Bisschop; Miranda J Velthuis; Harriët Wittink; Kees Kuiper; Tim Takken; Wout J T M van der Meulen; Eline Lindeman; Petra H M Peeters; Anne M May
Journal:  Sports Med       Date:  2012-05-01       Impact factor: 11.136

6.  Design of the Resistance and Endurance exercise After ChemoTherapy (REACT) study: a randomized controlled trial to evaluate the effectiveness and cost-effectiveness of exercise interventions after chemotherapy on physical fitness and fatigue.

Authors:  Caroline S Kampshoff; Laurien M Buffart; Goof Schep; Willem van Mechelen; Johannes Brug; Mai J M Chinapaw
Journal:  BMC Cancer       Date:  2010-11-30       Impact factor: 4.430

7.  Adherence to and satisfaction with low-intensity physical activity and supervised moderate-high intensity exercise during chemotherapy for breast cancer.

Authors:  Hanna van Waart; Laurien M Buffart; Martijn M Stuiver; Wim H van Harten; Gabe S Sonke; Neil K Aaronson
Journal:  Support Care Cancer       Date:  2019-08-08       Impact factor: 3.603

8.  Impaired physiological function and health-related QOL in patients before hematopoietic stem-cell transplantation.

Authors:  Shinichiro Morishita; Katsuji Kaida; Kazuhiro Ikegame; Satoshi Yoshihara; Kyoko Taniguchi; Masaya Okada; Norihiko Kodama; Hiroyasu Ogawa; Kazuhisa Domen
Journal:  Support Care Cancer       Date:  2011-04-09       Impact factor: 3.603

9.  Benefits of Physical Training in Sarcoidosis.

Authors:  Bert Strookappe; Jeff Swigris; Jolanda De Vries; Marjon Elfferich; Ton Knevel; Marjolein Drent
Journal:  Lung       Date:  2015-08-19       Impact factor: 2.584

10.  Severe sarcopenia might be associated with a decline of physical independence in older patients undergoing chemotherapeutic treatment.

Authors:  Hánah N Rier; Agnes Jager; Marieke C Meinardi; Joost van Rosmalen; Marc C J M Kock; Peter E Westerweel; Marija Trajkovic; Stefan Sleijfer; Mark-David Levin
Journal:  Support Care Cancer       Date:  2017-12-15       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.